Jelena Djuris

Dr. Jelena Djuris

Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy-University of Belgrade, Belgrade, Serbia
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Jelena DjurisJelena Djuris
Jelena Djuris
IOANNIS NIKOLAKAKISIOANNIS NIKOLAKAKIS
IOANNIS NIKOLAKAKIS
SISvetlana Ibric
Svetlana Ibric
ZDZorica Djuric
Zorica Djuric
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis

27 January 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Bojana B VidovićBojana B Vidović
Bojana B Vidović
DMDanijel D. Milinčić
Danijel D. Milinčić
Mirjana MarčetićMirjana Marčetić
Mirjana Marčetić
Jelena DjurisJelena Djuris
Jelena Djuris
TITijana Ilić
Tijana Ilić
Mirjana B. PešićMirjana B. Pešić
Mirjana B. Pešić
Goji berries have long been used for their nutritional value and medicinal purposes in Asian countries. In the last two decades, goji berries have become popular around the world and are consumed as a functional food due to wide-range bioactive compounds with health-promoting properties. In addition, they are gaining increased research attention as a source of functional ingredients with potential industrial applications. This review focuses on the antioxidant properties of goji berries, scientific evidence on their health effects based on human interventional studies, safety concerns, goji berry processing technologies, and applications of goji berry-based ingredients in developing functional food products.

1 October 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MMMladen Milović
Mladen Milović
Jelena DjurisJelena Djuris
Jelena Djuris
LĐLjiljana Đekić
Ljiljana Đekić
DVDragana Vasiljević
Dragana Vasiljević
SISvetlana Ibrić
Svetlana Ibrić

1 August 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DMDjordje Medarevic
Djordje Medarevic
Jelena DjurisJelena Djuris
Jelena Djuris
Panagiotis BarmpalexisPanagiotis Barmpalexis
Panagiotis Barmpalexis
Kyriakos KachrimanisKyriakos Kachrimanis
Kyriakos Kachrimanis
Svetlana IbricSvetlana Ibric
Svetlana Ibric
The development of stable solid dispersion formulations that maintain desired improvement of drug dissolution rate during the entire shelf life requires the analysis of drug-polymer solubility and miscibility. Only if the drug concentration is below the solubility limit in the polymer, the physical stability of solid dispersions is guaranteed without risk for drug (re)crystallization. If the drug concentration is above the solubility, but below the miscibility limit, the system is stabilized through intimate drug-polymer mixing, with additional kinetic stabilization if stored sufficiently below the mixture glass transition temperature. Therefore, it is of particular importance to assess the drug-polymer solubility and miscibility, to select suitable formulation (a type of polymer and drug loading), manufacturing process, and storage conditions, with the aim to ensure physical stability during the product shelf life. Drug-polymer solubility and miscibility can be assessed using analytical methods, which can detect whether the system is single-phase or not. Thermodynamic modeling enables a mechanistic understanding of drug-polymer solubility and miscibility and identification of formulation compositions with the expected formation of the stable single-phase system. Advance molecular modeling and simulation techniques enable getting insight into interactions between the drug and polymer at the molecular level, which determine whether the single-phase system formation will occur or not.

18 October 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMarijana Madzarevic
Marijana Madzarevic
DMDjordje Medarevic
Djordje Medarevic
AVAleksandra Vulovic
Aleksandra Vulovic
STSustersic Tijana
Sustersic Tijana
Jelena DjurisJelena Djuris
Jelena Djuris
Svetlana IbricSvetlana Ibric
Svetlana Ibric
The aim of this work was to investigate effects of the formulation factors on tablet printability as well as to optimize and predict extended drug release from cross-linked polymeric ibuprofen printlets using an artificial neural network (ANN). Printlets were printed using digital light processing (DLP) technology from formulations containing polyethylene glycol diacrylate, polyethylene glycol, and water in concentrations according to D-optimal mixture design and 0.1% w/w riboflavin and 5% w/w ibuprofen. It was observed that with higher water content longer exposure time was required for successful printing. For understanding the effects of excipients and printing parameters on drug dissolution rate in DLP printlets two different neural networks were developed with using two commercially available softwares. After comparison of experimental and predicted values of in vitro dissolution at the corresponding time points for optimized formulation, the R2 experimental vs. predicted value was 0.9811 (neural network 1) and 0.9960 (neural network 2). According to difference f1 and similarity factor f2 (f1 = 14.30 and f2 = 52.15) neural network 1 with supervised multilayer perceptron, backpropagation algorithm, and linear activation function gave a similar dissolution profile to obtained experimental results, indicating that adequate ANN is able to set out an input–output relationship in DLP printing of pharmaceutics.

18 October 2012 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Svetlana IbricSvetlana Ibric
Svetlana Ibric
Jelena DjurisJelena Djuris
Jelena Djuris
Jelena ParojcicJelena Parojcic
Jelena Parojcic
ZDZorica Djurić
Zorica Djurić
Implementation of the Quality by Design (QbD) approach in pharmaceutical development has compelled researchers in the pharmaceutical industry to employ Design of Experiments (DoE) as a statistical tool, in product development. Among all DoE techniques, response surface methodology (RSM) is the one most frequently used. Progress of computer science has had an impact on pharmaceutical development as well. Simultaneous with the implementation of statistical methods, machine learning tools took an important place in drug formulation. Twenty years ago, the first papers describing application of artificial neural networks in optimization of modified release products appeared. Since then, a lot of work has been done towards implementation of new techniques, especially Artificial Neural Networks (ANN) in modeling of production, drug release and drug stability of modified release solid dosage forms. The aim of this paper is to review artificial neural networks in evaluation and optimization of modified release solid dosage forms.